These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37565288)

  • 21. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
    Dadu R; Cabanillas ME
    Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer.
    Martínez-Trufero J
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):5-9. PubMed ID: 36202603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
    Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials.
    Su J; Fu Y; Wang M; Lin S
    Clin Endocrinol (Oxf); 2023 Feb; 98(2):275-276. PubMed ID: 35261050
    [No Abstract]   [Full Text] [Related]  

  • 27. Approach to the patient with advanced differentiated thyroid cancer.
    Schlumberger M; Sherman SI
    Eur J Endocrinol; 2012 Jan; 166(1):5-11. PubMed ID: 21890651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 29. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
    Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
    Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma.
    Coelho SM; Vaisman F; Buescu A; Mello RC; Carvalho DP; Vaisman M
    Braz J Med Biol Res; 2011 Jan; 44(1):73-7. PubMed ID: 21085896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
    Satapathy S; Bal C
    Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.
    Lin YS; Zhang X; Wang C; Liu YQ; Guan WM; Liang J
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3027-e3036. PubMed ID: 33769497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
    Wang E; Karedan T; Perez CA
    Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
    Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
    Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
    Berciano-Guerrero MÁ
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):40-46. PubMed ID: 36202609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and
    Leboulleux S; Benisvy D; Taieb D; Attard M; Bournaud C; Terroir-Cassou-Mounat M; Lacroix L; Anizan N; Schiazza A; Garcia ME; Ghuzlan AA; Lamartina L; Schlumberger M; Godbert Y; Borget I
    Thyroid; 2023 Sep; 33(9):1124-1129. PubMed ID: 37350119
    [No Abstract]   [Full Text] [Related]  

  • 38. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
    Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
    BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabrafenib Versus Dabrafenib + Trametinib in
    Busaidy NL; Konda B; Wei L; Wirth LJ; Devine C; Daniels GA; DeSouza JA; Poi M; Seligson ND; Cabanillas ME; Sipos JA; Ringel MD; Eisfeld AK; Timmers C; Shah MH
    Thyroid; 2022 Oct; 32(10):1184-1192. PubMed ID: 35658604
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.